<DOC>
	<DOCNO>NCT01244464</DOCNO>
	<brief_summary>This study design obtain post-marketing safety data IMOVAX Polio™ vaccine China . Primary Objective : To describe safety profile dose IMOVAX Polio™ administer 2 , 3 , 4 month age population age 2 month old living study city China .</brief_summary>
	<brief_title>A Study Safety IMOVAX Polio™ China</brief_title>
	<detailed_description>Study participant receive single dose IMOVAX Polio™ vaccine 2 , 3 , 4 month age , respectively . Each participant make total 7 visit . Safety monitor visit 30 day vaccination .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<criteria>Inclusion Criteria : Subject 2 month ( 6089 day ) old receive first dose polio vaccine . Subject 's parents/legal representative show willingness complete 3 primary dos fully use IMOVAX Polio™ accord schedule : one injection 2 , 3 , 4 month old , respectively . Informed consent form obtain subject 's parent/legal representative . Subject plan live select study site least three month inclusion . Exclusion Criteria : Subject history serious illness ( e.g. , hypersensitivity , seizure , convulsion , encephalopathy disease ) Known suspect impairment immunologic function Acute medical illness without fever within last 72 hour Subject plan leave study site least three month inclusion Administration immune globulin blood product within last three month Participation another clinical trial time Contraindication vaccination accord IMOVAX Polio™ leaflet .</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Poliomyelitis</keyword>
	<keyword>IMOVAX POLIO™</keyword>
	<keyword>Polio</keyword>
</DOC>